Cytolytic Capability Assay
Cytolytic Capability Assay - Related Videos
05:27
An In Vitro Assay to Study the Cytotoxic Capability of Cytokine-Induced Killer Cells
0 Views •
2025
This video demonstrates an in vitro technique to measure the cytotoxic ability of cytokine-induced killer (CIK) cells against cancer cells. Upon co-culturing target cancer cells with CIK cells, the dead cancer cells are identified using a fluorescent viability dye and are quantified using flow cytometry, estimating the cytotoxic effect of CIK cells.
07:05
In Vivo Assay for Detection of Antigen-specific T-cell Cytolytic Function Using a Vaccination Model
0 Views •
Cited by 4 •
2017
The goal of this protocol is to allow for detection of in vivo antigen-specific killing of a target cell in a murine model.
01:01
Hypersensitivity Reactions: Cytolytic Reactions
0 Views •
2026
Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
10:44
A Plate-based Cytotoxicity Assay for the Assessment of Rat Placental Natural Killer Cell Cytolytic Function
0 Views •
Cited by 2 •
2019
Here, we provide a detailed methodology to isolate and assess cytotoxic function of natural killer cells from placentas by a colorimetric plate assay. The reduced uterine perfusion pressure rat model of placental ischemia was chosen to demonstrate the antibody-mediated isolation and assessment of the cytotoxic function of natural killer cells.
02:52
Giemsa Staining for Colony Formation Assay: An In Vitro Staining Procedure to Assess Proliferative Capability of Mesenchymal Stem Cells
0 Views •
2025
In this video, we demonstrate the Giemsa staining procedure to assess the proliferative potential of mesenchymal stem cells to form viable colonies. Giemsa stain is a neutral stain primarily composed of azure and eosin dyes, which carry selective affinity for cellular components depending on their charge.
FAQs
The central comparison is between immune-effector activity and target-cell survival. Cytotoxic lymphocytes, including natural killer cells and T cells, are placed with cancer cells so killing can be assessed through target-cell lysis, reduced viability, or release of intracellular markers. These readouts connect immune-cell function to a measurable antitumor response.
The pairing determines which immune response and cancer-cell susceptibility are being examined. Using natural killer cells or T cells as effectors allows researchers to compare immune-cell activity, while selecting particular cancer cells helps characterize how susceptible tumor targets are to killing. This design makes the assay relevant to specific antitumor questions.
These measurements provide different observable indicators of target-cell damage or death. Lysis directly reflects disruption of the target cell, loss of viability indicates that cells no longer remain alive, and intracellular-marker release offers another measurable signal associated with killing. Selecting among these readouts helps align the assay with the experimental question.
A typical workflow begins by bringing cytotoxic lymphocytes and cancer cells together in co-culture. After the interaction period, researchers quantify target-cell death using lysis, viability loss, or intracellular-marker release. Comparing these measurements across immune-cell preparations, cancer-cell targets, or experimental conditions provides a functional assessment of antitumor killing.
The assay can reveal whether an immunotherapy changes the ability of immune effector cells to kill cancer targets. Researchers compare cytolytic measurements between experimental conditions to assess altered immune-cell activity or tumor susceptibility. This functional outcome complements other analyses and helps determine whether treatment-associated changes translate into cancer-cell killing.
Phenotypic and molecular measurements describe cellular features or molecular changes, whereas the cytolytic capability assay tests whether immune cells actually produce target-cell death. Using these approaches together connects mechanism or cell state with functional outcome. In cancer research, that combination can strengthen interpretation of antitumor immune responses.
Measured target-cell killing allows researchers to compare how different experimental conditions affect immune activity and cancer-cell susceptibility. By examining changes in lysis, viability, or intracellular-marker release, they can identify conditions that produce a clearer functional readout. This supports refinement of assay design and more consistent evaluation of antitumor responses.